Synlogic Reports Synthetic Biotic Medicines Show Anti-Tumor Response in Mouse Models

Synlogic (SYBX), a clinical-stage drug discovery and development company applying synthetic biology to probiotics to develop novel living medicines, reported late Monday preclinical data from its immuno-oncology program demonstrate that, in mouse models, the company’s Synthetic Biotic medicines were shown to stimulate an antitumor response and robustly reprogram the tumor microenvironment potentially enabling the treatment of a variety of cancers.

The company is focused initially on developing Synthetic Biotic medicines to treat so-called “cold tumors,” which lack infiltrating anti-tumor T-cells by first stimulating an innate anti-tumor response to make the tumor “hot” and then modifying the tumor microenvironment to enable T cell expansion and the development of memory, using a single agent to both prime T-cells to mount an immune response and sustain the response. Recent studies have demonstrated that activation of the stimulator of interferon genes (STING) pathway can play a critical role in the initiation of an anti-tumor immune response via activation of antigen presenting cells and presentation of tumor antigens.

Synlogic has engineered two new genetic circuits into E. coli Nissle, an immune “initiator” STING activating circuit (SYN-STING) and an immune “sustainer” kynurenine consuming circuit (SYN-Kyn). SYN-STING can be delivered directly into the tumor enabling its localized site of action. The company said the approach of using intra-tumoral injection elicits innate responses in the tumor but not in the circulation, potentially decreasing the risk of adverse events that may arise from the production of systemic type I interferon.

Leave a Reply

Your email address will not be published. Required fields are marked *